Table 2.
Effects of Targeted Cognitive Training on Cognition, Auditory Perception, Clinical Symptoms, and Medication
| TAU | TCT | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Outcome | Time 1 M (SD) | Time 2 M (SD) | Time 1 M (SD) | Time 2 M (SD) | b | SE | df | t | d |
| Speed of Processing | 27.73 (12.88) | 29.75 (10.62) | 29.25 (12.83) | 31.00 (13.44) | −0.07 | 2.74 | 32.33 | −0.03 | −0.01 |
| Attention & Vigilance | 31.09 (14.47) | 32.65 (16.65) | 29.83 (11.13) | 33.81 (13.66) | −0.26 | 3.00 | 32.05 | −0.09 | −0.03 |
| Working Memory | 32.36 (14.90) | 36.05 (17.50) | 31.75 (13.98) | 35.31 (11.25) | −2.33 | 2.36 | 31.43 | −0.99 | −0.29 |
| Verbal Learning | 33.09 (6.09) | 33.75 (9.33) | 32.75 (6.19) | 37.62 (6.18) | 4.13 | 1.86 | 33.22 | 2.21* | 0.65 |
| Visual Learning | 31.27 (11.22) | 33.35 (11.53) | 29.88 (10.83) | 32.25 (12.12) | −1.70 | 3.09 | 33.10 | −0.55 | −0.16 |
| Reas. & Prob. Solving | 39.82 (9.66) | 41.60 (10.31) | 41.12 (7.99) | 44.00 (7.51) | 1.35 | 4.35 | 37.61 | 0.31 | 0.09 |
| MCCB-NC | 23.95 (13.71) | 26.80 (14.77) | 23.12 (12.14) | 28.56 (9.80) | 0.69 | 2.48 | 31.72 | 0.28 | 0.08 |
| Words-In-Noise | 25.91 (3.70) | 25.15 (3.17) | 24.71 (2.93) | 26.38 (2.13) | 2.16 | 0.95 | 33.87 | 2.28* | 0.67 |
| SAPS | 4.45 (5.14) | 3.79 (4.08) | 5.12 (4.00) | 3.25 (4.37) | −1.38 | 0.88 | 31.12 | −1.57 | −0.46 |
| SANS | 6.18 (3.97) | 7.26 (4.81) | 7.75 (4.50) | 7.31 (3.91) | −0.74 | 1.62 | 33.80 | −0.46 | −0.13 |
| CPZs | 982 (758) | 993 (851) | 1329 (972) | 1190 (1082) | −13.42 | 94.38 | 28.44 | −0.14 | −0.04 |
Note. TAU = Treatment as Usual; TCT = Targeted Cognitive Training; MCCB-NC = MATRICS Consensus Cognitive Battery Neurocognitive Composite; SAPS = Scale for the Assessment of Positive Symptoms; SANS = Scale for the Assessment of Negative Symptoms; CPZs = chlorpromazine equivalent doses.
*
p < .05. Cohen’s d based on parameter estimates from linear mixed-effects models.